When genes are expressed at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By developing small-molecule medicines to control the expression of genes, we aim to make a profound difference in patients’ lives. We are advancing a growing pipeline of investigational medicines for diseases that have largely eluded other genomics-based approaches. Our current focus is on cancer and monogenic diseases.
SY-1425
SY-1425 is a first-in-class selective oral retinoid acid receptor alpha (RARα) agonist in clinical development for genomically defined subsets of patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.
View ProgramSY-2101
SY-2101 is a novel oral form of arsenic trioxide (ATO) in clinical development for patients with acute promyelocytic leukemia.
View ProgramSY-5609
SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor in development for patients with advanced breast, colorectal, lung, ovarian or pancreatic cancer, or with solid tumor types with an Rb pathway alteration.
View Program